Abstract
Introduction: Autotaxin (ATX) is an adipokine known to affect energy metabolism and lipid homeostasis. We aimed to evaluate serum ATX levels in metabolic-associated fatty liver disease (MAFLD) and other metabolic disorders in postmenopausal women. Methods: Postmenopausal women who received an annual health examination were included. The metabolic and demographic characteristics of the subjects were collected, including age, gender, weight, height, blood pressure, and biochemical parameters. Serum ATX level was determined by ELISA. Results: This cross-sectional includes 20 postmenopausal women and 20 age-paired healthy controls. MAFLD patients showed significant metabolic disturbance presented with increased body mass index (BMI), blood pressure (p < 0.001) and decreased high-density lipoprotein cholesterol (p < 0.05), as well as liver injury companied by elevated ALT (p < 0.05). Serum ATX levels were statistically higher in MAFLD (253.1 ± 52.1 vs. 202.2 ± 53.2 ng/mL; p < 0.01) and positively correlated with ALT (p < 0.001), γ-glutamyltransferase and BMI (p < 0.01), SBP and TG (p < 0.05). Higher ATX group demonstrated worsen metabolic states with greater proportion of MAFLD, higher BMI (p < 0.01), and ALT (p < 0.05). Logistic regression analysis revealed that serum ATX levels would positively independently predicted MAFLD (OR 1.049, 95% CI: 1.001–1.098, p < 0.05) with AUC of 0.763. Serum level of ATX is significantly elevated in hyperuricemia group (257.3 ± 60.9 vs. 214.5 ± 49.4 ng/mL; p < 0.05) and positively correlated with uric acid level (p < 0.01). Serum ATX would also act as diagnosing parameter of hyperuricemia with AUC of 0.706. Conclusions: Among postmenopausal women, serum ATX level is significantly elevated in MAFLD and related to multiple metabolic characteristics, especially hyperuricemia, which would thus serve as a potential noninvasive biomarker as well as a therapeutic target.
Journal Section:
Liver: Research Article
References
1.
Eslam
M
, Sanyal
AJ
, George
J
, International Consensus Panel
. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
. Gastroenterology
. 2020
;158
(7
):1999
–2014.e1
. 2.
Eslam
M
, El-Serag
HB
, Francque
S
, Sarin
SK
, Wei
L
, Bugianesi
E
, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
. Nat Rev Gastroenterol Hepatol
. 2022
;19
(10
):638
–51
. 3.
Scorletti
E
, Carr
RM
. A new perspective on NAFLD: focusing on lipid droplets
. J Hepatol
. 2022
;76
(4
):934
–45
. 4.
Loomba
R
, Friedman
SL
, Shulman
GI
. Mechanisms and disease consequences of nonalcoholic fatty liver disease
. Cell
. 2021
;184
(10
):2537
–64
. 5.
Lee
E
, Korf
H
, Vidal-Puig
A
. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
. J Hepatol
. 2023
;78
(5
):1048
–62
. 6.
Yuelling
LM
, Fuss
B
. Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties
. Biochim Biophys Acta
. 2008
;1781
(9
):525
–30
. 7.
Yung
YC
, Stoddard
NC
, Chun
J
. LPA receptor signaling: pharmacology, physiology, and pathophysiology
. J Lipid Res
. 2014
;55
(7
):1192
–214
. 8.
Meng
G
, Tang
X
, Yang
Z
, Zhao
Y
, Curtis
JM
, McMullen
TPW
, et al. Dexamethasone decreases the autotaxin-lysophosphatidate-inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer
. Faseb j
. 2019
;33
(2
):1899
–910
. 9.
D’Souza
K
, Paramel
GV
, Kienesberger
PC
. Lysophosphatidic acid signaling in obesity and insulin resistance
. Nutrients
. 2018
;10
(4
):399
. 10.
Fujimori
N
, Umemura
T
, Kimura
T
, Tanaka
N
, Sugiura
A
, Yamazaki
T
, et al. Serum autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease
. World J Gastroenterol
. 2018
;24
(11
):1239
–49
. 11.
Ikeda
H
, Kobayashi
M
, Kumada
H
, Enooku
K
, Koike
K
, Kurano
M
, et al. Performance of autotaxin as a serum marker for liver fibrosis
. Ann Clin Biochem
. 2018
;55
(4
):469
–77
. 12.
Flores-López
M
, García-Marchena
N
, Pavon
FJ
, Lara
E
, Porras-Perales
O
, Araos
P
, et al. Plasma concentrations of lysophosphatidic acid and autotaxin in abstinent patients with alcohol use disorder and comorbid liver disease
. Biomedicines
. 2021
;9
(9
):1207
. 13.
Masuda
A
, Fujii
T
, Iwasawa
Y
, Nakamura
K
, Ohkawa
R
, Igarashi
K
, et al. Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension
. Clin Chim Acta
. 2011
;412
(21–22
):1944
–50
. 14.
Ko
SH
, Jung
Y
. Energy metabolism changes and dysregulated lipid metabolism in postmenopausal women
. Nutrients
. 2021
;13
(12
):4556
. 15.
Eslam
M
, Newsome
PN
, Sarin
SK
, Anstee
QM
, Targher
G
, Romero-Gomez
M
, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement
. J Hepatol
. 2020
;73
(1
):202
–9
. 16.
Xu
C
, Chen
Y
, Xu
L
, Miao
M
, Li
Y
, Yu
C
. Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population
. Sci Rep
. 2016
;6
:23279
. 17.
Lee
JH
, Kim
D
, Kim
HJ
, Lee
CH
, Yang
JI
, Kim
W
, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease
. Dig Liver Dis
. 2010
;42
(7
):503
–8
. 18.
Kaffe
E
, Katsifa
A
, Xylourgidis
N
, Ninou
I
, Zannikou
M
, Harokopos
V
, et al. Hepatocyte autotaxin expression promotes liver fibrosis and cancer
. Hepatology
. 2017
;65
(4
):1369
–83
. 19.
Boucher
J
, Quilliot
D
, Pradères
JP
, Simon
MF
, Grès
S
, Guigné
C
, et al. Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression
. Diabetologia
. 2005
;48
(3
):569
–77
. 20.
Reeves
VL
, Trybula
JS
, Wills
RC
, Goodpaster
BH
, Dubé
JJ
, Kienesberger
PC
, et al. Serum Autotaxin/ENPP2 correlates with insulin resistance in older humans with obesity
. Obesity
. 2015
;23
(12
):2371
–6
. 21.
Brandon
JA
, Kraemer
M
, Vandra
J
, Halder
S
, Ubele
M
, Morris
AJ
, et al. Adipose-derived autotaxin regulates inflammation and steatosis associated with diet-induced obesity
. PLoS One
. 2019
;14
(2
):e0208099
. 22.
Rachakonda
VP
, Reeves
VL
, Aljammal
J
, Wills
RC
, Trybula
JS
, DeLany
JP
, et al. Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity
. Obesity
. 2015
;23
(5
):965
–72
. 23.
D’Souza
K
, Nzirorera
C
, Cowie
AM
, Varghese
GP
, Trivedi
P
, Eichmann
TO
, et al. Autotaxin-LPA signaling contributes to obesity-induced insulin resistance in muscle and impairs mitochondrial metabolism
. J Lipid Res
. 2018
;59
(10
):1805
–17
. 24.
Ferry
G
, Tellier
E
, Try
A
, Grés
S
, Naime
I
, Simon
MF
, et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity
. J Biol Chem
. 2003
;278
(20
):18162
–9
. 25.
Shao
X
, Uojima
H
, Setsu
T
, Okubo
T
, Atsukawa
M
, Furuichi
Y
, et al. Usefulness of autotaxin for the complications of liver cirrhosis
. World J Gastroenterol
. 2020
;26
(1
):97
–108
. 26.
Jose
A
, Kienesberger
PC
. Autotaxin-LPA-LPP3 Axis in energy metabolism and metabolic disease
. Int J Mol Sci
. 2021
;22
(17
):9575
. 27.
Qiu
H
, Song
E
, Hu
Y
, Li
T
, Ku
KC
, Wang
C
, et al. Hepatocyte-secreted autotaxin exacerbates nonalcoholic fatty liver disease through autocrine inhibition of the pparα/FGF21 Axis
. Cell Mol Gastroenterol Hepatol
. 2022
;14
(5
):1003
–23
. 28.
Erenel
H
, Yilmaz
N
, Cift
T
, Bulut
B
, Sozen
I
, Aslan Cetin
B
, et al. Maternal serum autotaxin levels in early- and late-onset preeclampsia
. Hypertens Pregnancy
. 2017
;36
(4
):310
–4
. 29.
Sakai
N
, Bain
G
, Furuichi
K
, Iwata
Y
, Nakamura
M
, Hara
A
, et al. The involvement of autotaxin in renal interstitial fibrosis through regulation of fibroblast functions and induction of vascular leakage
. Sci Rep
. 2019
;9
(1
):7414
. 30.
Brindley
DN
, Tang
X
, Meng
G
, Benesch
MGK
. Role of adipose tissue-derived autotaxin, lysophosphatidate signaling, and inflammation in the progression and treatment of breast cancer
. Int J Mol Sci
. 2020
;21
(16
):5938
. 31.
Zhao
Y
, Hasse
S
, Zhao
C
, Bourgoin
SG
. Targeting the autotaxin - lysophosphatidic acid receptor axis in cardiovascular diseases
. Biochem Pharmacol
. 2019
;164
:74
–81
. 32.
Maher
TM
, Ford
P
, Brown
KK
, Costabel
U
, Cottin
V
, Danoff
SK
, et al. Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials
. Jama
. 2023
;329
(18
):1567
–78
. 33.
Herr
DR
, Chew
WS
, Satish
RL
, Ong
WY
. Pleotropic roles of autotaxin in the nervous system present opportunities for the development of novel therapeutics for neurological diseases
. Mol Neurobiol
. 2020
;57
(1
):372
–92
. 34.
Federico
L
, Ren
H
, Mueller
PA
, Wu
T
, Liu
S
, Popovic
J
, et al. Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice
. Mol Endocrinol
. 2012
;26
(5
):786
–97
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
